Laigo Bio Extends Seed Round to €17 Million to Advance SureTACs Pipeline Toward the Clinic

New updates have been reported about Laigo Bio.

Laigo Bio has completed a second close of its seed financing, adding €5.5 million and lifting the round’s total to €17 million, capital that will be used to accelerate its SureTACs oncology programs and three additional candidates in autoimmune, immunology, and graft rejection. The new funding was co-led by incoming investor Biovance Capital alongside existing lead Kurma Partners, reinforcing investor conviction in Laigo’s precision membrane protein degradation strategy.

The company’s SureTACs platform engineers bispecific antibodies that link disease-driving membrane proteins to an optimal E3 ligase, triggering targeted ubiquitination and lysosomal degradation with high specificity and the potential for deeper pathway inhibition than conventional therapies. Management, led by CEO Dr. Matthew Baker, views this seed extension as a key step toward first-in-human studies in oncology and expanded discovery in autoimmune diseases, while Biovance’s Dr. João Incio highlights strong in vivo and in vitro efficacy data and an opportunity to address historically “undruggable” surface targets, supported by a broad investor syndicate spanning Kurma, Biovance, Curie Capital, Argobio Studio, Angelini Ventures, Eurazeo, Oncode Bridge Fund, ROM Utrecht Region, and Cancer Research Horizons.